glutathione and cell death Potentiation of loss nerve by the transition metals iron and copper: Implications for age-related neurodegenerative diseases Targeting the Vulnerability of Glutathione
Description
An ophthalmic formulation was evaluated in a Phase 2 randomized trial for severe dry-eye disease and was reported to be safe and well tolerated over the treatment period, with significant improvements in ocular signs and symptoms versus vehicle
No and this is important
This not only delays proper treatment but also makes downstream data analysis more difficult by introducing unknown sources of heterogeneity into the patient population
This is speculation based on known mechanisms, not a clinically validated protocol
